Welcome to
Accelerating drug development using biomedical imaging
Focus on MRI and Ultrasound
organized by PASREL-Imagerie
After a successful first edition, PASREL-Imagerie is delighted to announce the second edition of "Accelerating drug development using biomedical imaging" on February 9, 2024 at Cité Internationale Universitaire de Paris.
Dedicated to all biomedical stakeholders, the conference will highlight the translational role of MRI and Ultrasound in drug discovery.
Take this unique opportunity to:
- Listen to innovative projects by industrial and academic partners
- Discover the latest advances with expert speakers on non-isotopic imaging to de-risk medical innovations
- Develop your network
PLEASE NOTE THAT ALL ORAL COMMUNICATIONS WILL BE IN FRENCH.
The PASREL-Imagerie Team
Support
About PASREL-Imagerie
PASREL-Imagerie mission is to speed-up medical innovations with unrivaled translational in vivo imaging expertise and platforms.
PASREL-Imagerie provides state-of-the-art preclinical and clinical imaging to achieve your projects by bringing together:
- Longitudinal preclinical and clinical imaging: PET, MRI, Ultrasound, bi-photon microscopy, Multimodal Imaging, radiopharmaceuticals, etc.
- 4 complementary and multidisciplinary CEA centers (MIRCen, SHFJ, IDMIT
and Neurospin) investigating numerous therapeutic areas such as infectious diseases, neurodegenerative diseases, and oncology.
- A rich research environment: animal models and housing, behavior, viral vector, BSL 1-2-3 environments, etc.
From animal to patient, you have the opportunity to characterize pathophysiology of diseases, efficacy of drug candidates, compound biodistribution, and first tests in humans for example.
PASREL-Imagerie partners have thus access to a complete and powerful range of translational expertise and equipment through one-stop-shop to support their innovative developments.
About France Biotech
France Biotech, founded in 1997, is an independent association that brings together entrepreneurs in healthcare innovation and their expert partners.
As the driving force behind the healthcare innovation ecosystem and a privileged interlocutor for public authorities, France Biotech contributes to meeting the challenges of the HealthTech sector and proposing concrete solutions, in terms of competitiveness and attractiveness, through its 7 commissions and 4 working groups.
The aim is to help start-ups and SMEs in this sector to become high-performance international companies capable of rapidly designing and developing innovations, and ultimately making them accessible to patients.
